Project Grant HT94252410233
Award Date
4/1/24
Completion Date
3/31/27
Dollars Obligated
$6.2M
Federal Agency
Defense Health Agency
Awardee
Flugen Inc. (M9FHAR3RBML5)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Madison, WI 53711, USA
Similar Awards
Flugen Inc. was awarded a $5.6 million Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) for the period of April 1, 2023 through March 31, 2026. The grant will support Flugen's work to develop scalable manufacturing and toxicity testing methods for an intranasal M2SR influenza vaccine. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), is funding the development of self-assembled peptide nanoparticles (SAPNs) as a universal influenza vaccine platform. The $390,942 award to Georgia TECH Research Corp aims to assemble and characterize SAPNs displaying conserved influenza antigens, assess the vaccine effectiveness through different delivery...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Orlance, Inc., a woman-owned small business, a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an enhanced seasonal influenza DNA vaccine. The project aims to combine the advantages of a closely matched seasonal influenza vaccine with a universal influenza vaccine to provide more robust and durable protection, especially for the elderly and immunocompromised...
This federal Project Grant award from the United States Department of Agriculture's National Institute of Food and Agriculture, under the Agriculture and Food Research Initiative (AFRI) CFDA 10.310 program, provides $648,881 to the University of Maryland, College Park to develop a mucosal vaccine for influenza that can prevent initial and recurrent infections and reduce transmission between animals and humans. The goal is to create a universal influenza vaccine delivered through a nasal spray...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Scripps Research Institute to support research on developing a broad-spectrum influenza vaccine. The project aims to evaluate recently discovered neuraminidase (NA) broadly neutralizing antibodies (bNAbs) and use directed evolution techniques to design NA immunogens that can engage diverse bNAb precursors. This "germline...
This $456,390.00 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is intended to fund research to understand how antigen duration and vaccine construct modulate the infant immune response to influenza vaccines. Specifically, the research seeks to elucidate the mechanisms by which a prolonged antigen delivery approach can significantly increase protective antibody...
This $649,896 Project Grant award from the U.S. Department of Agriculture's (USDA) Agriculture and Food Research Initiative (AFRI) program (CFDA 10.310) will support research to develop an mRNA-based influenza vaccine for livestock. The project aims to create a vaccine cocktail containing mRNA encoding a chimeric hemagglutinin (HA) antigen with conserved HA stalk domains, along with an H5 antigen from highly pathogenic avian influenza (HPAI) H5N1. This vaccine will be delivered using a novel...
This Cooperative Agreement award of $638,820 from the Defense Health Agency supports an mRNA multivalent approach to develop an innovative malaria vaccine. The project, funded through the Military Medical Research and Development program (CFDA 12.420), aims to broaden the immune targets against malaria infection by including both pre-erythrocytic-stage antigens and mosquito saliva antigens. The Geneva Foundation, a non-profit research organization, will conduct this research over a 3-year period...
The Flavivirus and Alphavirus REVAMPP (FLARE) Center, funded by a $46,715,173 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), is developing and optimizing protein nanoparticle, virion-based, and mRNA vaccine platforms, as well as monoclonal antibody-based treatments to rapidly respond to emerging flaviviruses and alphaviruses with pandemic potential. The Center integrates the work of multiple...
This $300,387 Project Grant award, funded by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program, supports an "Integrated Precision Immunology Approach for Developing an Fc-Fusion Vaccine to Treat Frontotemporal Dementia" at Twilight Bioscience, Inc. in Topsfield, MA. The 2-year award period runs from February 1, 2025 to January 31, 2027 and aims to advance biomedical research initiatives focused on transforming...